BioAge Labs (NASDAQ:BIOA) Insider Sells $139,368.75 in Stock

BioAge Labs, Inc. (NASDAQ:BIOA) insider Paul Rubin sold 7,433 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total transaction of $139,368.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioAge Labs Price Performance

Shares of BIOA stock traded down $0.19 during mid-day trading on Tuesday, hitting $19.91. 381,085 shares of the stock traded hands, compared to its average volume of 1,006,004. BioAge Labs, Inc. has a 52-week low of $2.88 and a 52-week high of $24.00. The stock has a market cap of $713.77 million, a P/E ratio of -13.10 and a beta of 1.40. The stock’s fifty day moving average is $14.71 and its two-hundred day moving average is $8.85.

BioAge Labs (NASDAQ:BIOA) last announced its earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.11. The business had revenue of $2.05 million for the quarter.

Analyst Ratings Changes

A number of research firms have weighed in on BIOA. Piper Sandler initiated coverage on shares of BioAge Labs in a report on Tuesday, January 27th. They issued an “overweight” rating for the company. Citigroup raised their target price on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, January 27th. Finally, Wall Street Zen raised shares of BioAge Labs from a “sell” rating to a “hold” rating in a report on Tuesday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $15.00.

Institutional Trading of BioAge Labs

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock worth $9,709,000 after purchasing an additional 93,694 shares in the last quarter. Geode Capital Management LLC boosted its position in BioAge Labs by 60.8% in the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after buying an additional 171,426 shares during the period. Millennium Management LLC raised its stake in shares of BioAge Labs by 749.8% in the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after acquiring an additional 270,479 shares in the last quarter. Marshall Wace LLP increased its holdings in BioAge Labs by 324.7% during the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after purchasing an additional 173,388 shares during the period. Finally, Stonepine Capital Management LLC raised its position in BioAge Labs by 202.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares in the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.